Search PubMed⌕ Search

Biomedical subjects

K Orita

Publications and source records attributed to K Orita.

At least 397 records · Page 22Linked to original sources
PubMed1982

[Basic and clinical evaluations of cefmetazole in postoperative wound infections].

The time course of the concentration of cefmetazole (CMZ) in the serum and in skin and intestinal tissues was determined after a single intravenous injection of 2 g of the drug. CMZ moved into them well. Furthermore, 41 patients with postoperative wound infection (superficial in 29 and deep in 12) were treated with CMZ 2-4 g daily. Bacteriological examination of the lesions with simultaneously carried out. As a result, 101 strains of bacteria were isolated and identified. Mixed infection was found in 27 cases (65.9%). Fifteen strains (14.9%) of E. coli, 15 (14.9%) of B. fragilis, 7 (6.9%) of Klebsiella sp. and 7 (6.9%) of Proteus sp., were the main bacteria isolated. Eight cases (19.5%) had mixed infection of E. coli and B. fragilis. The committee (3 members) evaluated CMZ to be effective in 75.6% (31 of 41 cases) and bacteria disappeared in 60.5% (23 of 38 cases). The side effects observed were pyrosis and feeling of gastric malaise in 1 case. The results suggest that CMZ is useful, which exerts an excellent effect on postoperative wound infections.

Adolescent↗
PubMed1982

[Effect of immunochemotherapy on the cases of advanced gastric cancer stage III].

This study was conducted in patients with stage III gastric cancer who were admitted and gastrectomized in our Department of Surgery during July 1971 to March 1980. The control group consisted of 32 patients who were treated with mitomycin C and FT -207 during the first half of the period and the levamisole (LMS) group of 32 patients who were treated with the same regimen plus LMS during the latter half of the period. No significant statistical difference in their back ground factors was found. The LMS group was treated with 150 mg/day of LMS for 3 consecutive days every other week starting 3 days before operation. The follow-up study up to 30 postoperative months indicated an enhancing effect of LMS on the survival rate in patients with gastric cancer stage III undergoing curative resection. LMS proved to be effective on inhibition of the tumor growth when the tumor sizes ranged 4.0 to 7.9 cm, and the metastases were limited within the regional lymph node.

Drug Therapy, Combination↗
PubMed1982

[Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-tegafur combination therapy with or without levamisole. 1].

The effects of levamisole used in combination with Mitomycin C and Tegafur in patients with resectable stomach cancer were investigated in 10 cooperative institutes. The patients were randomly allocated to the treatment with either control or levamisole by envelope method. Levamisole group was treated with Mitomycin C (day 0, 20 mg, day 1, 10 mg, one shot i.v.), Tegafur (600 mg/day, p.o.) and levamisole (150 mg/day, p.o.). Levamisole was administered 3 consecutive days prior to surgery, and 3 consecutive days every fortnight after surgery. The control group was administered Mitomycin C and Tegafur. The both drugs were administered by the same method as above. Two hundred and twenty-two patients were entered in this trial. However, with the exclusion of 67 patients, the eligible patients were 155, consisting of 77 in the control group and 78 in the levamisole group. In stage III patients, the disease-free interval and survival time were significantly prolonged in the levamisole group compared to the control group (generalized Wilcoxon test p less than 0.05). The side effects were observed a little more frequently in the levamisole group. However, there was no significant difference. From this result, it can be considered that levamisole is effective in delaying recurrence and in prolonging survival time of the patients when used in combination with adjuvant chemotherapy after resection of stomach cancer.

Adjuvants, Immunologic↗
PubMed1982

[Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-5-FU combination therapy with or without levamisole. 1].

A randomized controlled study by envelope method was carried out with the purpose of evaluating effects and side effects of levamisole in patients with resectable stomach cancer. The patients were randomly allocated to the treatment either with control or levamisole according to the indication of the envelope opened at least 3 days prior to surgery. The control group was treated with Mitomycin C (day 0, 20 mg day 1, 10 mg, one shot i.v.) and 5-FU(150 mg/day, p.o.). The levamisole group was treated with Mitomycin C, 5-FU and levamisole. Levamisole was administered at a daily dose of 150 mg for 3 consecutive days before surgery, and the 3 consecutive days administration schedule was repeated every fortnight for one year after surgery. Four hundred and forty-six patients were entered in this trial. However, with the exclusion of 104 patients as exceptions and dropouts, the total eligible patients were 342, consisting of 167 in the control group and 175 in the levamisole group. The effects were evaluated by comparing the disease-free interval or the survival time of both groups. There was no significant difference in the disease-free interval and survival. In this study, we have not yet reached the conclusion that levamisole is effective in prolonging disease-free interval and survival time, because high survival rates are still maintained in both groups for 2 years after surgery. The final conclusion would be drawn with the follow-up results in the future.

Adjuvants, Immunologic↗
PubMed1982

[Antitumor effect of polysaccharide lentinan on C3H/He mice bearing MH134 ascites hepatoma].

1. Lentinan inhibited the proliferation of MH 134 ascites hepatoma transplanted subcutaneously into C3H/He mice, but its most favorite effect appeared when 1mg-2mg/Kg of lentinan was administered for 10 consecutive days from the eighth day after tumor transplantation, yielding a tumor proliferation-inhibition rate of 33% in the average tumor diameter. 2. In studying the average survival days by the chemotherapy of mitomycin C (MMC), 5-fluorouracil (5-FU), and cytosine arabinoside (Ara-C) in combination with lentinan, when both of these substances were administered concurrently in the second week of the tumor transplantation, average survival time was 29.2 days as compared to 20.5 days in the untreated group, 25.1 days in the group administered lentinan alone, and 22.0 days in the group receiving chemotherapy alone. 3. When the antitumor activity of lentinan was studied by the change in the macrophage migration inhibition activity (MI), it was found that in the untreated group MI activity disappeared on the 14th day after tumor transplantation, while in the group treated with lentinan observation of a positive activity in the spleen cells suggested a restorative action of lentinan of the immunity suppression accompanying the tumor growth.

Animals↗
PubMed1982

[Intralymphatic administration of BCG-CWS in advanced malignant melanoma].

BCG-CWS was administrated into lymphatic vessels in the treatment of advanced malignant melanoma metastasized to the lymph node of the posterior peritoneum. Side effects consisted of fever, lymphangitis, a decrease in urinary output and a slight rise in serum GOT, there being no serious side effects. Clinically, tumor mass in the abdomen cleared but metastases to the other organs increased, and the patient died of general dispersion of the disease. At autopsy, the abdominal mass became flat, with the cut surface of yellowish brown color. Histologically, this mass formed necrosis made up of destroyed tumor cells and histiocytes. BCG-CWS mediated histiocyte response appeared to destroy tumor cells. Thus, it is possible that local administration BCG-CWS could elicit a potent response even in advanced carcinoma. Since the contact of BCG-CWS with tumor cells produced this response, administration of BCG-CWS into the lymphatic vessels may be indicated where the lymph current to the metastasized lymph node is not obstructed. This treatment would be effective particularly in the case of micrometastasis, and there is a possibility that it could elicit a specific response.

Aged↗
PubMed1982

[Effect of NK-421 (Bestatin) and Ge-132 on the cytotoxicity of spleen cells obtained from the tumor-bearing mice].

The effect of NK-421(Bestatin) and Ge-132 (an organic germanium compound) on the ADCC and natural killing (NK) activities of the spleen cells of MH-134 tumor-bearing mice were studied. In the tumor-bearing mice, the ADCC activity was enhanced, and NK activity was reduced in accordance with the progress of the tumor. By oral administration of Bestatin at doses of 5, 10 and 50 mg/kg, ADCC activity was potentiated, and at a dose of 10 mg/kg, NK activity was significantly increased. Intraperitoneal administration of Ge-132 at 50 mg/kg potentiated the ADCC activity of tumor-bearing mice. A higher activity was observed in the plastic dish adherent fraction. Ge-132 also potentiated the reduced NK activity of tumor-bearing mice to higher level than normal mice. The elevated activities of ADCC and NK following Bestatin and Ge-132 administration were decreased with anti-Thy-1 antibody and complement; however, the percent reduction was lower compared to that of the control cancer animals. This result indicates that Bestatin and Ge-132 may act on non-T cells and augment ADCC and NK activities.

Adjuvants, Immunologic↗
PubMed1982

[Experimental and clinical studies of bestatin as an immunomodulator].

The experimental and clinical effects of bestatin were examined and the results obtained were as follows. Bestatin which is an immunomodulator discovered by Umezawa did not increase the bone marrow stem cells examined by the method of the spleen colony assay in the 60Co irradiated mouse. However, it prolonged the survival time slightly when it was administered 10-25mg/kg intraperitoneally. Clinically, bestatin was administered to the patients with gastrointestinal cancer. It did not influence on the PHA-induced lymphocyte blastformation rate, but it increased the peripheral lymphocyte count and PPD skin reaction in the cases of curative resection and increased the peripheral lymphocyte counts in the cases of nonresection after 1 month of the operation.

Adjuvants, Immunologic↗
PubMed1982

[Antitumor effect of Corynebacterium parvum on C3H mouse bearing MH-134 tumor].

The antitumor effect of Corynebacterium parvum (C. parvum) was examined by using C3H/He mouse bearing MH-134 ascites hepatoma. The optimal dose of C. parvum was 0.4mg/day intraperitoneally for 5 consecutive days from the 5th day after tumor inoculation. The cell-mediated immunity in this treatment was also investigated by delayed type hypersensitivity (DTH) and macrophage migration inhibition activity (MI). According to the results of both DTH and MI, it was assumed that C. parvum yielded an antitumor effect by restoring the cell-mediated immunity of the tumor bearing host.

Animals↗
PubMed1980

Immunochemotherapy of gastric cancer with levamisole.

In 156 cases of gastric cancer, levamisole (LMS) was administered at a daily dose of 150 mg for three consecutive days every other week. The administration was started 3 days before operation. This medication was repeated for more than one month. The survival rate up to two years after surgery was studied. The survival rate was not affected in patients with Stage I and II gastric cancer, but in patients with Stage III, the difference in the survival rate between the LMS group and the control group was significantly higher than that in the control group (p less than 0.05). In patients with Stage IV, the survival rate in the LMS group was higher than that in the control group although the difference was not significant. In patients of Stage III and IV, the effect of LMS on the survival rate was highest in cases with curative resection (p less than 0.01). In cases with noncurative resection, the difference between the LMS group and the control group was greatest (24.4%) 12 months after surgery but not significant (p less than 0.5), and also in cases without resection the difference between the two groups was greatest (20.3%) 12 months after surgery but not significant (p less than 0.2).

Adjuvants, Immunologic↗